"503A" and "503B" are sections of the federal Food, Drug, and Cosmetic Act. Section 503A dates to the Food and Drug Administration Modernization Act of 1997. After the 2012 fungal meningitis outbreak traced to a compounding pharmacy, Congress reaffirmed 503A and created the 503B outsourcing-facility category with the Drug Quality and Security Act of 2013. Both describe legitimate compounders. They differ in who they answer to, what they can make without a prescription, and whether you can keep their products as office stock.
503A: the traditional compounding pharmacy
A 503A pharmacy compounds a medication for an individual patient against a specific prescription. This is the classic "the doctor wrote it, the pharmacy made it for this one patient" model.
- Overseen primarily by state boards of pharmacy, following USP compounding standards (USP <795> for non-sterile, <797> for sterile).
- Not required to register with the FDA as an outsourcing facility and not held to full drug-manufacturing cGMP.
- Compounds only against a prescription for an identified individual patient. That is federal law, not a state preference: FDA's position is that 503A pharmacies may not distribute compounded drugs as office stock regardless of what state rules allow. Office stock is what 503B facilities exist for.
- Best for customized formulations: a specific testosterone concentration, a combination injectable, a tailored peptide blend.
503B: the FDA-registered outsourcing facility
A 503B outsourcing facility is a category created specifically so clinics and hospitals could buy compounded medications as office stock, without a prescription for each patient.
- Voluntarily registers with the FDA and is inspected on a risk-based schedule.
- Must follow cGMP, the same current good manufacturing practice standards that govern drug manufacturers.
- Can compound in larger batches without patient-specific prescriptions, which is what makes office stock possible.
- Best for the in-office injectables you administer from the shelf rather than dispense to a named patient.
503A vs 503B at a glance
| 503A Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Primary oversight | State board of pharmacy | FDA (registers & inspects) |
| Manufacturing standard | USP <795> / <797> | Full cGMP |
| Patient-specific Rx required | Yes | No |
| Office stock (non-patient-specific) | No (FDA position: patient-specific Rx required) | Yes (its core purpose) |
| Batch size | Small, per-prescription | Larger batches |
| Typical clinic use | Custom patient formulations | In-office injectable stock |
Which one does a TRT, peptide, or GLP-1 clinic use?
In practice, most cash-pay specialty clinics use both. You lean on a 503A pharmacy when a patient needs a customized compound: a non-standard testosterone concentration, a combination injectable, a peptide formulation written for that person. You lean on a 503B outsourcing facility for the injectables you keep on the shelf and administer in the office, where buying per-patient scripts would be impractical.
Compounded GLP-1s like semaglutide are the case where this framework gets misread. The 503A/503B split determines your workflow only when compounding the drug is permissible at all, and for GLP-1s that threshold question turns on current FDA shortage status and the federal copy restrictions: a 503B facility may not compound what is essentially a copy of an approved drug, and a 503A pharmacy may do so only when the prescriber documents a clinically significant difference for that specific patient. That window has opened and closed repeatedly. Compounding was broadly permitted while the branded products sat on the FDA shortage list, then the restrictions re-engaged when FDA declared the tirzepatide and semaglutide shortages resolved in late 2024 and early 2025. Do not assume the answer from what other clinics are doing; verify the current status with your pharmacy and counsel at the time you order. The sourcing decision, brand versus compounded and what it does to your pricing model, is covered in our guide to starting a GLP-1 clinic.
The operational catch: using both means two supplier relationships, two ordering workflows, and two sets of lot numbers and expiration dates to track, on top of the DEA recordkeeping any controlled substance already demands. That tracking burden is where most clinics' spreadsheets break down.
Choosing and vetting a pharmacy
Two constraints catch new operators before quality ever comes up. First, licensure follows the patient: a 503A pharmacy needs a non-resident pharmacy license in every state it ships into. A telehealth clinic seeing patients in ten states needs a pharmacy licensed in all ten, not just its home state, and more than one multi-state expansion plan has died on that detail. Second, beyond-use dating caps how much you can usefully order: compounded preparations carry short BUDs compared with manufactured drugs, so a stock-up-for-the-quarter shipment can expire on the shelf before you work through it.
On diligence, ask for records rather than reassurance: the facility's FDA inspection history and any Form 483 observations (FDA publishes both), certificates of analysis from independent testing on the specific preparations you plan to buy, and its recall record. A pharmacy that hesitates to produce any of the three is telling you something.
What this means for your EHR and inventory
The 503A/503B split isn't just a procurement detail. It's a documentation obligation. Whatever you administer or dispense, you need to know the exact lot, the expiration date, the quantity remaining, and which patient received which lot, in a record that holds up to a board or DEA audit.
This is exactly what Moonshot Clinic was built to handle. It supports multiple suppliers across both 503A and 503B facilities, tracks inventory at the lot level with first-expired-first-out dispensing, deducts down to the milligram when a medication is charted, and keeps an immutable transaction trail with audit-ready reports. Compounded orders can be placed right from the patient chart.
- Controlled-substance tracking built to support DEA recordkeeping requirements (21 CFR Part 1304): lot-level, mg-level, FEFO, immutable audit trail
- E-prescribing & compounded ordering: order from the chart, no separate login
- EHR for peptide clinics and GLP-1 weight-loss clinics
- What to look for in TRT clinic software: the full evaluation checklist for hormone practices
This guide is general information for clinic operators, not legal, regulatory, or pharmacy-compliance advice. FDA guidance on compounding changes over time, especially for drugs like GLP-1s tied to shortage lists. Confirm current requirements with your pharmacy partners, your state board, and qualified counsel before making procurement or clinical decisions.